Maintenance Notice

Due to necessary scheduled maintenance, the JMIR Publications website will be unavailable from Wednesday, July 01, 2020 at 8:00 PM to 10:00 PM EST. We apologize in advance for any inconvenience this may cause you.

Who will be affected?

Accepted for/Published in: JMIR Diabetes

Date Submitted: Nov 14, 2022
Open Peer Review Period: Nov 14, 2022 - Nov 21, 2022
Date Accepted: Feb 3, 2023
Date Submitted to PubMed: Feb 7, 2023
(closed for review but you can still tweet)

The final, peer-reviewed published version of this preprint can be found here:

The Effectiveness of an App (Insulia) in Recommending Basal Insulin Doses for French Patients With Type 2 Diabetes Mellitus: Longitudinal Observational Study

Nevoret C, Gervaise N, Delemer B, Bekka S, Detournay B, Benkhelil A, Bahloul A, d'Orsay G, Penfornis A

The Effectiveness of an App (Insulia) in Recommending Basal Insulin Doses for French Patients With Type 2 Diabetes Mellitus: Longitudinal Observational Study

JMIR Diabetes 2023;8:e44277

DOI: 10.2196/44277

PMID: 36749650

PMCID: 10018375

Effectiveness of Insulia® App in French Patients with Type 2 Diabetes Mellitus treated with Basal Insulin. A Longitudinal Observational Study

  • Camille Nevoret; 
  • Nathalie Gervaise; 
  • Brigitte Delemer; 
  • Said Bekka; 
  • Bruno Detournay; 
  • Amine Benkhelil; 
  • Amar Bahloul; 
  • Geneviève d'Orsay; 
  • Alfred Penfornis

ABSTRACT

Background:

For patients with Type 2 diabetes (T2DM), calculating daily dose of their basal insulin may be challenging. INSULIA® is a digital remote monitoring solution that uses clinical algorithms to recommend basal insulin doses.

Objective:

Our study was designed to assess the clinical impact of this device in real-life setting.

Methods:

retrospective observational analysis of data collected through the device in adult French patients with T2DM treated with basal insulin ± oral antihyperglycemic agents using the system since at least 6 months was conducted.

Results:

Of the 484 users, 373 (77.0%) performed at least one dose calculation. 59.2% were men. When they started to use the app, mean age, BMI, HbA1c, and basal insulin dose were respectively: 55.8 years (SD: 11.9), 30.6 kg/m2 (SD: 5.9), 10.1% (SD: 2.0) and 25.5 IU/day (SD: 15.8). Over a median duration of use of 5.0 [3.8-5.7] months, patients have used the system 5.8 times/week (SD 1.6) on average and 73.4% of their injected doses were consistent with the doses suggested by the app. Among regular and compliant user patients (n=91, ≥5 measurements/week and ≥80% adherence to calculated doses), 60.4% achieved the FBG target (±5%) at 6 months while the incidence of reported hypoglycaemia has decreased (-0.16%/month). Among 82 patients for whom measures were available, mean HbA1c decreased from 9.9% to 7.2% at 6 months.

Conclusions:

In real life, an improvement in glycaemic control without increasing hypoglycaemic risk is observed in patients regularly using the INSULIA® application and following the dose recommendations of the algorithm. Clinical Trial: NA


 Citation

Please cite as:

Nevoret C, Gervaise N, Delemer B, Bekka S, Detournay B, Benkhelil A, Bahloul A, d'Orsay G, Penfornis A

The Effectiveness of an App (Insulia) in Recommending Basal Insulin Doses for French Patients With Type 2 Diabetes Mellitus: Longitudinal Observational Study

JMIR Diabetes 2023;8:e44277

DOI: 10.2196/44277

PMID: 36749650

PMCID: 10018375

Download PDF


Request queued. Please wait while the file is being generated. It may take some time.

© The authors. All rights reserved. This is a privileged document currently under peer-review/community review (or an accepted/rejected manuscript). Authors have provided JMIR Publications with an exclusive license to publish this preprint on it's website for review and ahead-of-print citation purposes only. While the final peer-reviewed paper may be licensed under a cc-by license on publication, at this stage authors and publisher expressively prohibit redistribution of this draft paper other than for review purposes.